- Investing Ideas
- /
- Indian Pharmaceuticals & Biotech Established, Profitable and Undervalued
Indian Pharmaceuticals & Biotech Established, Profitable and Undervalued
UPDATED Aug 08, 2022
Over $1bn in market cap, profitable and undervalued based on cash flows.
1 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CIPLACipla | ₹1,029.55 | 2.5% | 12.8% | ₹830.8b | ₹1,098.05 | PE33.4x | E17.4% | 0.5% |
Page 1 of 1